GlassScriptPhysician profile
Hector Ubaldo
NPI 1790795383
$6,428.76
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $130 · 2021: $273 · 2022: $371 · 2023: $487 · 2024: $5,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $4,934 · Food and Beverage: $506 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $4,933.59 |
| Food and Beverage | $505.85 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photonicare INC | $4,933.59 | 2024 | Otosight Middle Ear Scope |
| Abbott Laboratories | $326.84 | 2022-2023 | Freestyle Libre 3 |
| Novo Nordisk INC | $212.12 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $119.01 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Antares Pharma, INC. | $97.88 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $85.00 | 2023 | |
| Abbvie INC. | $69.40 | 2021-2023 | Qulipta |
| Pfizer INC. | $60.03 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.13 | 2021 | |
| Amarin Pharma, INC. | $45.59 | 2020 | |
| Halozyme INC | $44.84 | 2023 | |
| Sanofi-Aventis U.S. LLC | $32.44 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $29.12 | 2021 | |
| Corium, LLC | $24.86 | 2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $21.67 | 2022 | Tlando, Xyosted |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $21.06 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Verity Pharmaceuticals INC. | $20.62 | 2024 | Tlando |
| Neuronetics, INC. | $20.54 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.72 | 2023 | Seglentis, Livalo |
| Sumitomo Pharma America, INC. | $18.59 | 2024 | Gemtesa |
| Renalytix Ai, INC. | $17.39 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Allergan, INC. | $17.18 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.33 | 2022 | |
| Hikma Pharmaceuticals USA | $14.95 | 2019 | |
| Amgen INC. | $14.88 | 2023 | Otezla, Repatha |
| Lilly USA, LLC | $14.46 | 2024 | Mounjaro |
| Acerus Pharmaceuticals Corporation | $13.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.87 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.85 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $11.43 | 2020 | |
| Fidia Pharma USA INC. | $11.42 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Ubaldo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.